Clene Inc. has updated its prospectus supplement on May 8, 2024, to adjust the maximum aggregate gross sales price of its common stock offering to $12,300,000. This amendment is filed with the SEC and modifies the previous prospectus supplement dated November 7, 2023, and the accompanying prospectus dated April 26, 2022. The sales of the common stock will be conducted through Canaccord Genuity LLC, acting as the sales agent, on an 'at the market offering' basis as defined by Rule 415(a)(4). Canaccord Genuity is entitled to a commission of up to 3.0% per share sold and will also receive indemnification against certain liabilities. Clene's common stock and public warrants are traded on the Nasdaq under the symbols 'CLNN' and 'CLNNW,' with the last reported sale prices on...Show More

Clene Inc. has updated its prospectus supplement on May 8, 2024, to adjust the maximum aggregate gross sales price of its common stock offering to $12,300,000. This amendment is filed with the SEC and modifies the previous prospectus supplement dated November 7, 2023, and the accompanying prospectus dated April 26, 2022. The sales of the common stock will be conducted through Canaccord Genuity LLC, acting as the sales agent, on an 'at the market offering' basis as defined by Rule 415(a)(4). Canaccord Genuity is entitled to a commission of up to 3.0% per share sold and will also receive indemnification against certain liabilities. Clene's common stock and public warrants are traded on the Nasdaq under the symbols 'CLNN' and 'CLNNW,' with the last reported sale prices on May 6, 2024, being $0.4236 and $0.0393, respectively. The company's public float was valued at approximately $37.0 million as of the date of the supplement. Clene Inc. has not sold any shares under the General Instruction I.B.6 of Form S-3 in the 12 months preceding the date of the new prospectus supplement. The company warns that investing in its securities carries a high degree of risk.